Drug Trial Radar · NCT07744126
A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Sep 1, 2026
Primary completion
Oct 2029
Study completion Oct 2029
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Aug 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Head and neck squamous cell carcinoma (HNSCC) is the seventh most common cancer worldwide with an annual incidence of approximately 700,000 cases. This study aims to evaluate the change in disease activity and optimal dose, and optimal dose of telisotuzumab adizutecan in combination with pembrolizumab as first-line treatment in participants with recurrent or metastatic head and neck squamous cell carcinoma. Telisotuzumab adizutecan is an investigational drug being developed for the treatment of recurrent or metastatic HNSCC. Participants are placed into 3 treatment groups called treatment arms. Each group receives a different treatment. Adult participants diagnosed with recurrent or metastatic HNSCC who have not received prior systemic therapy for advanced disease and whose tumors express c-Met protein will be enrolled. Approximately 180 participants will be enrolled in the study at sites worldwide. Participants will receive intravenous doses of telisotuzumab adizutecan with intravenous pembrolizumab, or standard of care (SOC) chemotherapy with pembrolizumab. Participants will receive treatment as part of a 67 weeks study duration. There may be higher treatment burden for participants in this trial compared to their standard of care due to study procedures. Participants will attend regular visits every 3 weeks during the study at a hospital or clinic. The effects of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Conditions
- Head and Neck Squamous Cell Carcinoma
Interventions
Telisotuzumab AdizutecanDrug
Intravenous (IV)
PembrolizumabDrug
IV
CarboplatinDrug
IV
CisplatinDrug
IV
FluorouracilDrug
IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Adverse Events (AE)sTime frame: Up to Approximately 67 weeks
- Objective Response (OR) Rate Based on Blinded Independent Central Review Assessment per Response Evaluation Criteria in Solid Tumors Version 1.1Time frame: Up to Approximately 67 weeks
- Progression-Free Survival (PFS) Based on Blinded Independent Central Review Assessment per Response Evaluation Criteria in Solid Tumors Version 1.1Time frame: Up to Approximately 67 weeks
Locations
9 sites in 3 countries. Site status is shown where the registry gives one.
City Of Hope Comprehensive Cancer Center /ID# 281939
Duarte, California · Recruiting
City of Hope - Atlanta /ID# 285268
Newnan, Georgia · Recruiting
Kobe University Hospital /ID# 281770
Kobe, Hyōgo, Japan · Recruiting
Saitama Medical University International Medical Center /ID# 282932
Hidaka, Saitama, Japan · Recruiting
Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 281506
Kaohsiung City, Taiwan · Recruiting
China Medical University Hospital /ID# 281502
Taichung, Taiwan · Recruiting
National Taiwan University Hospital /ID# 281513
Taipei, Taiwan · Recruiting
Taipei Veterans General Hospital /ID# 281531
Taipei, Taiwan · Recruiting
Linkou Chang Gung Memorial Hospital /ID# 281529
Taoyuan City, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.